COMMUNIQUÉS West-GlobeNewswire

-
Company update: Global Kinetics Corporation hits significant clinical milestones on its trajectory to revolutionise the treatment of Parkinson’s disease
21/08/2018 -
Emerald Health Therapeutics Announces Appointment of Pure Sunfarms President and CEO
21/08/2018 -
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
21/08/2018 -
Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma
21/08/2018 -
Bionano Genomics Announces Pricing of Initial Public Offering
21/08/2018 -
CCAB Partners With ImmunoBiochem as it Launches New Co-Development Strategy to Advance Early-Stage Biotech Companies
21/08/2018 -
Princeton Facial Plastic Surgeon Introduces NovaThreads to Practice
21/08/2018 -
Progressive Care Inc. Reports 47% Increase in Prescriptions Filled During July 2018
21/08/2018 -
GBT Appoints Heidi L. Wagner as Senior Vice President, Government Affairs and Policy
21/08/2018 -
Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer
21/08/2018 -
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
21/08/2018 -
CLS Holdings USA Names Matthew Janz as VP of Marketing and Director of Operations at Oasis Cannabis
21/08/2018 -
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
21/08/2018 -
Biotricity Expands Salesforce to Cover Key US Markets and Begins Advisory Board Expansion to Move Into Preemptive Heart Disease Diagnostics
21/08/2018 -
Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference
21/08/2018 -
VitalHub Announces Sale of TREAT EHR System to Youth Mental Health Facility
21/08/2018 -
Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research
21/08/2018 -
Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium
21/08/2018 -
Auxly Announces Acquisition of Leading Canadian Contract Research Organization KGK Science
21/08/2018
Pages